A snakebite can become a medical emergency within minutes or hours, depending on the species, the amount of venom injected and where the bite occurs. Snake venom can interfere with blood clotting, damage muscles and tissues, attack the nervous system, or cause severe bleeding and organ damage.
One of the most remarkable medical treatments for serious snake envenoming is antivenom. But antivenom is not a simple chemical that destroys venom. It is a biological medicine made using the immune response of animals.
So, how is antivenom made? And once it enters the human body, how does it actually stop venom from causing further damage?
Let's take a closer look.
Antivenom, also called snake antivenom immunoglobulin, is a preparation containing antibodies that can bind to and neutralize components of specific snake venoms.
The antibodies are generally produced by animals such as horses or sheep. These animals are carefully immunized with selected venom preparations so their immune systems develop antibodies against the venom. The antibody-rich plasma is then collected, processed and purified to make the final medicine.
This is an important distinction: antivenom is not venom that has been chemically "turned off." Instead, venom is used to train another animal's immune system to produce antibodies.
Those antibodies are subsequently purified and given to a person who has been envenomed.
The human immune system can make antibodies when it encounters foreign substances. Snake venom contains many proteins and other molecules that the immune system recognizes as foreign.
Scientists take advantage of this natural immune response.
A carefully controlled venom preparation is introduced to a suitable donor animal in a professionally managed immunization programme. The amount and schedule are designed to stimulate antibody production while protecting the animal's health. WHO guidance emphasizes veterinary supervision, appropriate immunization protocols and good manufacturing practices throughout this process.
Over time, the animal develops a strong antibody response against the venom components.
These antibodies are the raw material for antivenom.
The process starts with venom from medically important snake species.
Specialized facilities maintain venomous snakes and collect venom under controlled conditions. The venom is then processed, identified and stored according to strict procedures.
This step is more important than it might sound.
A snake's venom can vary depending on its species, geographical location, age and other factors. WHO therefore emphasizes the importance of selecting venoms that appropriately represent the snakes responsible for clinically important bites in the region where the antivenom will be used.
The selected venoms may eventually be combined into mixtures used for immunization.
The prepared venom is then used to immunize donor animals, most commonly horses in conventional commercial production.
The horse receives carefully controlled doses according to a planned immunization schedule. The purpose isn't to make the horse sick. Instead, the treatment stimulates its immune system to recognize venom components and produce antibodies.
The animal receives repeated immunizations and boosters while veterinarians monitor its health and immune response.
Horses have become particularly useful because they can produce large quantities of plasma and are well suited to this type of biological production. Sheep and some other animals can also be used.
This part is essentially immunology.
The immune system recognizes molecules in the venom as foreign. B cells respond by producing antibodies that specifically recognize venom components.
After repeated exposure, the animal develops a high concentration, or titre, of venom-specific antibodies in its blood.
Those antibodies are what manufacturers ultimately want.
Once the animal has developed an adequate immune response, blood or plasma is collected under controlled veterinary and manufacturing procedures.
Modern production commonly uses plasmapheresis, in which plasma is collected while red blood cells can be returned to the animal. This helps reduce blood loss and anaemia compared with repeatedly removing whole blood.
The collected plasma contains many different proteins, including the desired antibodies.
But it is obviously not ready to be injected into a patient yet.
It has to undergo extensive processing.
The next major stage is purification.
Plasma contains albumin, clotting proteins, antibodies and many other biological components. Manufacturers therefore use controlled fractionation and purification techniques to isolate the immunoglobulin fraction containing the useful venom-binding antibodies.
Depending on the manufacturing process, the final active material may contain whole IgG antibodies or antibody fragments such as F(ab')₂ or Fab.
This purification stage is critical because the final medicine must meet requirements for identity, purity, safety and potency.
Additional processing steps can include filtration and chromatography, depending on the product and manufacturing technology.
After purification, the antibody preparation is converted into a pharmaceutical product.
Manufacturers carefully formulate the purified antibodies so they remain stable and retain their ability to neutralize venom.
Some antivenoms are supplied as liquid preparations, while others may be freeze-dried (lyophilized) and later reconstituted before use.
The product is then filled into sterile containers and labelled according to regulatory requirements.
Making antibodies isn't enough. Manufacturers must demonstrate that the resulting antivenom is suitable for medical use.
Quality-control testing can examine factors such as:
WHO's assessment framework includes laboratory analysis of both the venoms used to produce antivenom and the resulting antivenom, along with evaluation of manufacturing practices.
This testing is particularly important because an antivenom needs to work against the venom profile for which it was designed.
This is the most fascinating part.
Think of venom as a mixture of biological weapons and antibodies as highly specialized molecular binders.
After a venomous bite, toxins circulate through the body and interact with specific targets. Depending on the snake, these toxins may interfere with nerves, muscles, blood coagulation, blood vessels or tissues.
Antivenom introduces antibodies that can recognize and bind to venom components.
Imagine a venom toxin as a key that fits into a lock on a particular biological target.
The toxin needs to reach that target to produce its harmful effect.
An antivenom antibody can bind to the toxin first.
Once the antibody attaches to the toxin, the toxin may no longer be able to interact effectively with its target.
In simplified terms:
Venom toxin + Antibody → Antibody-toxin complex → Reduced toxin activity
The body's normal clearance mechanisms can then help remove the antibody-toxin complexes.
WHO describes antivenoms as containing antibodies capable of binding venom components and enabling the body to eliminate those toxins.
Not exactly.
This is one of the most common misconceptions.
Antivenom generally doesn't chemically destroy venom molecules. Instead, its antibodies bind to venom components and neutralize their biological activity.
The exact mechanism varies according to the antibodies and toxins involved.
Some antibodies may prevent toxins from reaching their molecular targets. Others can interfere with the toxin's ability to interact with cells or tissues.
The result is that the venom's harmful effects can be stopped or reduced.
Antivenom is most useful when venom toxins are still accessible to antibodies.
Once a toxin has already caused irreversible damage to tissues, nerves or other organs, neutralizing the remaining toxin cannot necessarily reverse that damage.
For example, if a neurotoxin has already disrupted neuromuscular function, antivenom can neutralize circulating venom that remains available, but recovery from the injury may still take time.
This is why serious snake envenoming requires urgent medical assessment.
WHO describes antivenom as the specific treatment for snakebite envenoming and emphasizes rational use in appropriate clinical circumstances.
Not every antivenom works against every snake.
A monovalent or monospecific antivenom is designed to neutralize venom from a particular snake species.
It can be highly targeted when the responsible snake is known and the product is appropriate.
A polyvalent antivenom is designed to cover multiple medically important snake species.
This can be extremely useful in regions where identifying the exact snake after a bite is difficult.
For example, antivenoms used in some parts of South Asia are formulated to cover several clinically important species rather than only one. WHO notes that polyvalent products are intended to neutralize venoms from several species relevant to a particular geographical area.
The trade-off is that the effectiveness of an antivenom depends on whether its antibody coverage matches the venom involved.
Snake venoms are remarkably diverse.
Even closely related snake species can have different venom compositions. Venom may contain neurotoxins, cytotoxins, enzymes, procoagulant or anticoagulant components and other biologically active molecules.
An antibody raised against one venom component may not effectively neutralize a different toxin.
There can also be paraspecific neutralization, where antibodies raised against one venom recognize and neutralize toxins from a related species. But this cannot simply be assumed for every snake.
This is why antivenom development requires knowledge of the medically important snakes and their venoms in the region where the medicine will be used.
Yes.
Antivenoms are biological products, and conventional products are commonly derived from animal plasma. As a result, some patients can experience adverse reactions.
The risk depends on the product, its formulation, purification and the individual patient.
Possible reactions can include allergic-type reactions, and delayed reactions can also occur.
Modern manufacturing focuses heavily on purification, formulation and quality control to improve safety. WHO notes that the physicochemical properties of antivenom, including protein aggregation, can influence adverse reactions.
This is one reason antivenom should be administered in a proper medical setting where the patient can be monitored and treated if a reaction occurs.
No.
The two products work in very different ways.
A vaccine trains your own immune system to develop protection, generally before you encounter the infection or toxin.
Antivenom provides ready-made antibodies.
That means antivenom can provide immediate passive protection against susceptible venom components, rather than requiring the patient's immune system to spend days developing its own antibody response.
This difference is particularly important in snakebite because waiting for the body to produce sufficient antibodies would be far too slow during a serious envenoming.
The process can be summarized like this:
Snake venom collection
↓
Venom selection and quality control
↓
Preparation of immunizing venom mixtures
↓
Controlled immunization of horses or other donor animals
↓
Development of high antibody levels
↓
Plasma collection
↓
Plasma fractionation and antibody purification
↓
Further purification/formulation
↓
Quality and potency testing
↓
Sterile filling, labelling and release
This overall process is consistent with the production framework described in WHO's antivenom guidelines.
Traditional animal-plasma-derived antivenoms remain the mainstay of treatment, but researchers are exploring newer approaches.
Scientists are investigating monoclonal antibodies, recombinant antibodies, humanized antibodies and small-molecule inhibitors that could potentially target individual venom toxins with greater precision.
The long-term goal is not simply to make antivenom easier to manufacture. Researchers also want treatments that are safer, more consistent, easier to store and capable of providing broader protection against diverse venom toxins.
However, these newer approaches are still part of a developing field and do not replace conventional antivenom in current clinical practice.
Antivenom is one of the clearest examples of medicine borrowing a natural process from the immune system.
A dangerous venom is first used, under tightly controlled conditions, to stimulate an animal's immune response. The animal produces antibodies against venom components. Those antibodies are then collected from plasma, purified, formulated and rigorously tested.
When administered to an envenomed patient, the antibodies bind to susceptible venom components and prevent them from continuing to damage the body's tissues.
So, in a very real sense, antivenom works because one animal's immune system has been trained to help protect another species.
And while the concept sounds straightforward, producing a safe and effective antivenom is a highly controlled biological manufacturing process involving venom science, immunology, veterinary medicine, pharmaceutical purification and extensive quality testing.
Q1. How is antivenom made?
Antivenom is made by immunizing animals, commonly horses, with carefully controlled venom preparations. Their plasma is then collected and processed to purify venom-specific antibodies.
Q2. How does antivenom work?
Antivenom contains antibodies that bind to venom toxins. This can prevent the toxins from interacting with their targets and helps the body remove the antibody-toxin complexes.
Q3. Is antivenom made from snake venom?
Yes, snake venom is used during the production process. Carefully prepared venom stimulates the animal's immune system to produce antibodies that can recognize and neutralize venom components.
Q4. Can antivenom completely reverse a snakebite?
Antivenom can neutralize venom that remains susceptible to its antibodies, but it cannot necessarily reverse damage that has already occurred. Prompt medical treatment is therefore important.
Q5. Does one antivenom work against every snake?
No. Antivenoms are designed to target specific venom profiles. Some are monovalent for one species, while polyvalent antivenoms are designed to cover several medically important snakes.
Comments